Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Low-dose V180 with low-dose ISCOMATRIX adjuvant · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Low-dose V180 with low-dose ISCOMATRIX™ adjuvant | EXPERIMENTAL | - |
| Low-dose V180 with medium-dose ISCOMATRIX™ adjuvant | EXPERIMENTAL | - |
| Medium-dose Non-adjuvanted V180 | EXPERIMENTAL | - |
| Medium-dose V180 with low-dose ISCOMATRIX™ adjuvant | EXPERIMENTAL | - |
| Medium-dose V180 with medium-dose ISCOMATRIX™ adjuvant | EXPERIMENTAL | - |
| Medium-Dose V180 with Alhydrogel™ adjuvant | EXPERIMENTAL | - |
| High-dose Non-adjuvanted V180 | EXPERIMENTAL | - |
| High-dose V180 with low-dose ISCOMATRIX™ adjuvant | EXPERIMENTAL | - |
| High-dose V180 with medium-dose ISCOMATRIX™ adjuvant | EXPERIMENTAL | - |
| Low-dose V180 with high-dose ISCOMATRIX™ adjuvant | EXPERIMENTAL | - |
| Medium-dose V180 with high-dose ISCOMATRIX™ adjuvant | EXPERIMENTAL | - |
| High-dose V180 with high-dose ISCOMATRIX™ adjuvant | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Low-dose V180 with low-dose ISCOMATRIX™ adjuvant | BIOLOGICAL | Three 0.5-mL intramuscular doses of low-dose V180 containing low-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2 |
| Low-dose V180 with medium-dose ISCOMATRIX™ adjuvant | BIOLOGICAL | Three 0.5-mL intramuscular doses of low-dose V180 containing medium-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2 |
| Medium-dose V180 (non-adjuvanted) | BIOLOGICAL | Three 0.5-mL intramuscular doses of medium-dose V180 with no adjuvant at Months 0, 1, and 2 |
| Medium-dose V180 with low-dose ISCOMATRIX™ adjuvant | BIOLOGICAL | Three 0.5-mL intramuscular doses of medium-dose V180 containing low-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2 |
| Medium-dose V180 with medium-dose ISCOMATRIX™ adjuvant | BIOLOGICAL | Three 0.5-mL intramuscular doses of medium-dose V180 containing medium-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2 |
| Medium-dose V180 with Alhydrogel™ adjuvant | BIOLOGICAL | Three 0.5-mL intramuscular doses of medium-dose V180 containing Alhydrogel™ adjuvant at Months 0, 1, and 2 |
| High-dose V180 (non-adjuvanted) | BIOLOGICAL | Three 0.5-mL intramuscular doses of high-dose V180 with no adjuvant at Months 0, 1, and 2 |
| High-dose V180 with low-dose ISCOMATRIX™ adjuvant | BIOLOGICAL | Three 0.5-mL intramuscular doses of high-dose V180 containing low-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2 |
| High-dose V180 with medium-dose ISCOMATRIX™ adjuvant | BIOLOGICAL | Three 0.5-mL intramuscular doses of high-dose V180 containing medium-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2 |
| Low-dose V180 with high-dose ISCOMATRIX™ adjuvant | BIOLOGICAL | Three 0.5-mL intramuscular doses of low-dose V180 containing high-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2 |
| Medium-dose V180 with high-dose ISCOMATRIX™ adjuvant | BIOLOGICAL | Three 0.5-mL intramuscular doses of medium-dose V180 containing high-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2 |
| High-dose V180 with high-dose ISCOMATRIX™ adjuvant | BIOLOGICAL | Three 0.5-mL intramuscular doses of high-dose V180 containing high-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2 |
| Placebo | BIOLOGICAL | Three 0.5-mL intramuscular doses of phosphate-buffered saline at Months 0, 1, and 2 |
Selected Inclusion Criteria: * In good health * Voluntarily agrees to participate by giving written informed consent * Able to read, understand, and complete study questionnaires * Able to complete all scheduled visits and comply with study procedures * Access to a telephone * Agrees to avoid unusu...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 5 | PHASE3 | Tetravalent Dengue Vaccine |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE2 | EYU688 |
| Sanofi SA Sponsored ADR | SNY | 1 | - | Undisclosed |
| Abbott Laboratories | ABT | 1 | - | Undisclosed |
| Danaher Corporation | DHR | 1 | - | Undisclosed |
Low-dose V180 with low-dose ISCOMATRIX adjuvant is an investigational vaccine being studied for the prevention of dengue. It is a monoclonal antibody modality developed by Merck & Company, Inc. (MRK). The vaccine is currently in Phase 1 clinical development for dengue.
Low-dose V180 with low-dose ISCOMATRIX adjuvant is developed by Merck & Company, Inc., which trades under the ticker MRK. The company is conducting clinical trials to evaluate this investigational dengue vaccine in healthy adults.
Low-dose V180 with low-dose ISCOMATRIX adjuvant is in Phase 1 clinical development. It is an investigational vaccine and has not been approved by regulatory authorities. One Phase 1 trial has been completed, with 98 participants enrolled.
Low-dose V180 with low-dose ISCOMATRIX adjuvant was studied in a completed Phase 1 trial, NCT01477580, titled "Study of a Dengue Vaccine (V180) in Healthy Adults (V180-001)." The trial enrolled 98 healthy adults aged 18 years and older, with all sexes included.
Yes, Low-dose V180 with low-dose ISCOMATRIX adjuvant is a formulation of the V180 dengue vaccine candidate. The completed clinical trial NCT01477580 refers to the vaccine as V180, and this low-dose combination with ISCOMATRIX adjuvant is being evaluated for dengue prevention.